NDAINTRAVENOUSSOLUTION3 Generics Approved
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
38/100
Clinical Trials
5
Data completeness
4/8 — Partial
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUZYTTIR is an intravenous formulation of cetirizine hydrochloride, a second-generation H1-receptor antagonist. It is indicated for the treatment of allergic conditions in patients requiring intravenous administration when oral routes are not feasible. The drug works by selectively blocking peripheral H1 receptors, reducing histamine-mediated allergic responses.
$0.616MPart D
Peak3.7 years to LOEPeak-stage product with modest Part D utilization suggests a niche hospital/acute care positioning with limited commercial expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Started Mar 2020
34 enrolled
Oncology Patients Receiving Chemotherapy
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition
Started Jan 2006
30 enrolled
Healthy
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
Started Jan 2006
30 enrolled
Healthy
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions
Started Jul 2005
40 enrolled
Allergies
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions
Started Jun 2005
40 enrolled
Allergies
Worked on QUZYTTIR at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.